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Two assay methods have been developed and valjdated for the 
analysis of chlorproguanil and chlorcycloguanil. The gas 
chromatographic procedur~ with electron-capture detector 
( GC-ECD) was developed for the analysis of chlorproguani 1 
while a reverse phase liquid chromatographic procedure with 
ultra-violet detector at 235nm (HPLC-UV) was developed to 
assay for chlorcycloguanil alone. 
The gas chromatographic procedure developed, using 
proguani.l as the internal standard, gave good resolution 
for proguanil and chlorproguanil. A linear response was 
obtained over the rang~ 1.0 - 50.0ng. The average recovery 
for, chlorproguanil was 80.8 + 5. 4%. Extraction recoveries 
were linear for chlorproguanil within the range 2.0-40ng/ml 
( c o e ·f f i c i en t o f c o r r: e 1 a t i o n = o . 9 9 6 ) . •r he w i t h i n - day 
precision for chlorproguanil gave coefficient of variation 
between 4. 9% - 7. 9% at1d day-to-day pred 1; ion \.Jas between 
0.72 - 7.3%. The assay sensitivity was 0.1 ng/ml for 
chlorproguanil. 
In the HPLC procedure cycloguanil was used as the internal 
standard. Detector linearity for chlorcycloguanil was 
obta.ined over the range· J • 0 - 80 ng. The average recovery 
of chlocycloguanil was found to be 99.4 + 5.6%. The 
xiii 
within-day coefficient of variation was between 1.8% - 6.8% 
and day-to-day was 4. 5 9. 2%. The limit of assay 
sensitivity by HPLC-U~ was 0.5ng/ml. 
The pharmacokinetic study on healthy Malaysian volunteers 
was carried out. Chlorproguanil is well tolerated an6 safe 
Ln all subjects receiving 20 mg of Lapudrine tablet 
administered as a single oral dose. In our study one 
subject appears to absorb chlorproguanil to a limited 
extent. The mean Cmax for chlorproguanil was 25 + 4 ng/ml 
and the mean tmax was 3.0 ± 1.2 hour. Chlorproguanil has a 
mean t 1 ; 2 of 37.1 + 19.5 hour and a mean plasma CL of 0.93 
f 0.26 L/hr/kg. The mean Vd was 51.1 ! 38.1 L/kg while the 
mean AUC 0 _ ex 365 + 101 ng hr/ml was observed. 
Chlorcycloguanil was measurable in only two subjects 
and the mean AUC 0 _ ~ in these subjects was 147.6 ± 11.0 ng 
. hr/ml. The mean Cmax and tmax for all subjects were 6.7 + 
5.0 ng/ml and 5.6 ~ 3.0 hour respectively. Our study 
indicates that there are slight pharrnacokinetic differences 
of chlorproguanil in Malaysian volunteers as compared to 
those derived in the Caucasian subjects. Factors such as 
dose size weight of the subjects and genetics may 
contribute to the differences in the. pharrnacokinetic 
parameters of chlorproguanil in ltealthy volunteers. 
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PENGESAHAN KAEDAH hAGI PENGESEIAN CHLORPROGUANIL DAN 
CHLORCYCLOGUANIL DAN APLIKASINYA KEPADA KAJIAN 
FARMAKOKINETIK 
ABSTRAK 
Dua kaedah pengeseian telah dikembangkan dan disahkan bagi 
analfsis klorproguanil dan klorsikloguanil. Kaedah gas 
kromatografi penangkap elektron (KG-ECD) telah dikembangkan 
bagi pengeseian chlorproguanil sementara kaedah 
kromatografi cecair Keupayaan tinggi fasa terbalik dengan 
pengesan ultra lembayung pada 235nm (KCKT-UV) telah 
dikembangkan bagi pengeseian klorsikloguanil sahaja. 
Didalam kaedah gas kromatografi yang dikembangkan, 
proguanil digunakan sebagai piawai dalaman. Proguanil dan 
klorproguanil didapati menunjukkan resolusi yang baik 
didalam pemisahan yang di j a lankan. Keluk tentukuran bagi 
pengesan adalah bergaris linear bagi pengesanan dalam 
julat 1.0-SO.Ong. Purata paratus pengembalian bagi 
klorproguanil adalah 80.8 ± 5.4%. Keluk tentukuran piawai 
bagi klorproguanil pdalah linear b<HJi julat kepekatan 
2. 0-40ng/ml (pekali koefisien = 0. 996). Peratus pekali 
ubahan bagi kepresisan dalam sehari bagi klorproguanil 
adalah diantara 4.9% - 7.9% and kepresisan dari hari ke 
hari adalah diantara 0.72- 7.3!.'6. Had pengesanan bagi 
XV 
klorproguanil melalui KG-ECD adalah 0.1 ng/ml. 
DHlnm kaedah kromalograf.i cecaj r keupayaan tinggi yang 
dikembangkan sikloguanil telal1 digunakan sebagai piawai 
da l.amnn . Kelinearan pengesanan te lah d.idapati bagi julat 
1. 0 - 80 ng. Purata peratus pengembalian klorsikloguanil 
adalah 99.4 + 5.6%. Peratus pekali ubahan bagi 
kepresisan dalam sehari adalah diantara 1.8% - 6.8% dan 
bagi dari hari ke hari adalah 4.5 - 9.2%. Had pengesanan 
klorsikloguanil melaui kaedah KCKT-UV .:F!d 1 nh 0. 5ng/ml. 
Kajinn farmakokinetik keatas sukarelawan sihat Malaysia 
telah dijalankan. Toleransi klorproguanil adal.ah baik dan 
selamat bagi kesernua subjf~k yang rnenerima tablet: 20 mg 
Lapudrine yang diberikan secara oral. Dalam kajian ini 
satu subjek didapati tidak menyerap drug ini dengan baik. 
Purata Cmax bagi klorproguanil yang diperolehi ialah 25 ± 
4 ng/ml dan purata t~ax adalah 3.0 ± 1.2 jam. Purata t 112 
pula ialah 37.1 .± 19.5 jam dan purata CL bagi plasma 
adalah 0.93 + 0.26 L/jam/kg. Purata Vd adalah 51.1 + 38.1 
L/kg sementara purata bagi AUC 0 _ ~ adalah 365 + 101 ngjam 
/ml. Klorsikloguanil hanya dapat ditentukan pada dua orang 
subjek sahaja dan purata AUC 0 _ <X bagi subjek-subjek ini 
adalah 147.6 + 11.0 ng jam/ml. Purata bagi Cmax dan tmax 
kesemua subjek adalah 6.7 ± 5.0 ng/ml dan 5.6 + 3.0 jam. 
Kajlan ini telah menunjukl~;an terdapat sedikit perbezaan 
farmakokinetik bagi klorproguanil diantara sukarelawan 
s:ihat Malaysia dengan subjek dari golougan Ko.ul\asian. 
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Kaul<as ian. Faktor- faktor sc~perti dos, saiz berat subjek 
dan genetik seseorang boleh mernpengaruhi parameter 
farmakokinetik klorproguanil bagi sukarelawan sihat ini. 
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1.0 Introduction 
1.1 Extent of the disease 
Malaria is one of the oldest disease mentioned in the 
early writings of Egypt, India and China. The clinical 
symptoms were fully described decades ago by Hippocrates, 
but until today the outcome of malaria infection is still 
unpredlctablo. 
Malaria is caused by 
species of parasite. 
striking as AIDS, it 
P. _ falciparum the most deadly 
Eventhough malaria is not as 
is still affecting hundreds of 
millions of people. Between 1-2 
in the next decade ( Time,l993). 
millions will die from it 
For many years, malaria control by chemotherapy give 
promising result. Tho powdered roots of Ch'ang Shen 
(Dichron Lebrifuges) and Qing hao (Artemisinia annua) was 
used in China as treatment for at least 2000 years. Only 
in the seventeenth Century the new remedy was discovered ; 
the isolation of th~ alkaloids from the Cinchona bark which 
soon established various salts of quinine, the first potent 
remedy against malatia. 1~e inability to supply quinine to 
meet the great demand during the first and second world 
wars brought about a new development of other synthetic 
antimalarial dru~s. Scientists started searching for new 
dr~gs and began to understand the pathology of malaria. 
They produced a library of invaluable antimalarj_al 
compounds such as 8-aminoquinoline series, 
4-aminoquinoline, the dihydrofolate reductase inhibitors 
and etc. Chloroquine, derived from quinine, is a miracle 
drug developed during the war which was a relatively 
i~~xpensive prophylactic and treatment drug that saved many 
lives. 
The vector control via the introduction of effective 
insecticides such as dichlorodiphenyltrichloroethane (DDT) 
also helped to combat the disease and these were then 
endorsed by WHO in the concept of malaria eradi.cation 
programme. Vector control which was given an integrated 
plan in 1956 together with the successful use of the drug, 
chemoprophylaxis almost controlled malaria in 1950s. 
However, a new and menacing event in the history of malaria 
occurred in 1960s. The discovery that 
appeared to build up resistance to chloroquine and the 
increasing number of reports in the resistance of human 
plasmodia to other prciphylaxis drugs such as proguanil and 
pyrimethamine had cauf.ied some disappointment in 
chemotherapy (Bruce-Chwatt, 1986) Also, DDT was 
ineffective in many areas owing to diiferin9 habits of 
Ano_pheles which llas developed resistance to the 
insecticide (Warhurnt, 1987). This causes the loss of 
effectiveness in vector control. 
The threat posed by resUrgent malaria in many parts of the 
world becomes critical as such the WHO has adopted a global 
strategy. Eradication, the dogma of the 1960s, is no 
longer considered realistic. Since malaria occurs under 
differing conditions, WHO is seeking to have malaria 
control integrated into government planning in health care, 
sanitation and development projects, which have sometimes 
served to help spread the disease (Time, 1993). 
Drugs, however still play a key role in the control of 
malnria particularly in preventing death and reducing 
morbidity. This situatlon has stimulated research into a 
better and more effective usage of the currently available 
drugs, the development of new antimalarial agents and the 
introduction of drug co~binations. 
·1.1. 1 Malaria life tycle[ 
Most antimalarial drugs target on the particular stages of 
development of the malaria parasites. Knowledge of its 
life-cycle is important for the propc~r deployment of these 
antimalarial drugs. The true malaria parasites belong to 
the genus _R_lasmodium(P)_ with 4 pathogenic species,~!... 
vivax. The 
human plasmodia exhibit two typr:!S of schizogony 
(exoerythrocytic w .i. thout pigment and erythrocytic with 
pigment) in the human host and a sexual stage tenninating 
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in sporogony in Anopheles mosquito. 
During the blood menl, the sporozoites which reside in the 
salivary gland of the mosquito is injected into the blood 
stream and enter~ the liver parenchymous cells a~d 
undergoes one cycle of asexual division to form 
multi-nucleate shizonts. The pre-erythrocytic tissue 
schizogony state ib completed when the tissue schizonts 
undergo endoplasmic fission, producing thousands of 
unin~cleate merozoite§ and causes rupture to the liver 
cells. In this form~ the parasite invades the erythrocytes, 
grows and multiplie~ cyclically from trophozoites to mature 
blood schizonts. Malaria pigment (h<•emozoin) is produced 
within the parasite during this stage by the breakdown of 
the erythrocytes haemoglobin causing a fever which is the 
symptom of the disease. Some intra-erythocytic forms 
-develop into male or female of sexual parasites 
(gametocytes), whic~ will unite to form zygote on eniering 
the stomach of the ~osquito. Eventually, after the gradual 
stages of ookinete and oocyts, large numbers of sporozoites 
are produced and stored in the salivury glands of the 
l1popheles, which will be transmitted in the next blood 
meal. In most strains of h vivax and apparently ~ 
ovnle the sporozoites which enter the hepatic cells may 
delay their develop~ent and remain as dormant hypnozoites. 
After responding to an unknown stimulus or to a 
preprogrammed genetic message they begin to give rise to 
merozoites which escape from the liver and infect 
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erythrocytes whish caused relapse attacks (Krotoski 1985). 
For P._. !!Jalar_iae and !?_._fill_<! iQarum, some recent evidence show 
that schizogony in these species and the ·recrudescence 1 
may originate from erythr0cyctic forms remaining in tho 
body for a considerable time. Relapse of vivax, and ovale 
malaria may occur at intervals for 3 or 4 years while the 
·recrudescence 1 in £.. falcl.l?arum infection seldom occur 
more than 1 year after the primary attack but J... malariae 
may per~ist in the blodd for 20 - 50 years. 
1.1. 2 Site of actidn of_antimalarial dr~ 
A biological classific~tion of antimalarial given here is 
largely based on the oJtline by Warhurst (1987). 
1 .. Tissue schizoiltocides inhibit the growth of the 
parasite in the liver cell. Drugs used are the 'causal 
prophylacti~S 1 and this include the dihydrofolate reductase 
inhibitors, proguanil and pyrimethamine which were used 
alone or in combination and sulphonamides. 
2. Hypnozonitocides (Peters, 1983) kill the dormant liver 
stages (hypnozoites) and used as 'antirelapse· drugs in ~ 
y_i'.'<l.'S. and_...E...:_ ova],_g_. Primaquine and other 8-aminoquinoline 
are the only examples that have been found effective iu 
man. 
3. Blood schizontocicles act rapidly only on the 
erythrocytic stage arid are generally attached in therapy. 
The drugs acting at this stage with fast action are the 
cinchona alkaloids (quinine, quinidine) 
4-aminoquinolines (chioroquine) , the sesquiterpene lactones 
(eg. artemisinin, artcnrether, arteether and sodium 
artesunate) , the novel 4-quinolinemethanols (mefloquine) 
and the phenanthrenerriethanols (halofantrine). These drugs 
have a marked action while dihydrofolate reductase 
inhibitors (pyrimethamine, proguanil, chlorproguanil), 
sulphonamides, sulphones, ant i.biotics and to a small 
degree primaquine also have a relatively slow 
blood-schizontocidal effects which also act on other 
stages. 
4. Gametocides will destroy the sexual stages of the 
·parasites in the blood including the mature gametocytes of 
P. falciparum. The 8-aminoquinoline drugs, especially 
primaquine are used for this purpose. 
5. Sporontocides refer to the inhibitory action of the 
drug or its metabolite in the blood meals on the subsequent 
development of the oocycts and sporozoites in the mosquito. 
Drug with this action include the dihydrofolill:r~ reductase 
i.nhibitors (pyrimetha~ine and proguanil). 'Sporontocide' 
when fed directly to ~osquito will inhibit oocycts and 
sporozoite growth (pyrimethamine and cycloguanil). 
---------------·---------···--·---------------------
1.1. 3 Drug resistance in malaria 
Drug resistance in malaria has been defined as the ability 
of a parasite strain to survive and/or to multiply despite 
the administration and absorption of a drug given in doses 
equal to a higher than those usually recommended but within 
the limits of tolerance of the subject (Bruce-Chwatt, 
1986). 
Resistance by PlasmQ.fl-l_!:!m to individual antimalarial 
compounds has been reportad in many parts of the world and 
often involves cross-reQistance to the other compounds. 
Drugs that Plasmodiu~ was found to be resistant in many 
parts of the world are the DHFR inhibi~ors, 
4-aminoquinoline (chloroquine, amodiaquj ne) quinine, 
primaquine, mefloquine, sulphonamides and sulphones 
(Bruce-Chwatt, 1986). 
Resistance of P. falcipq_r_!!.!!l..!._ to chloroquine is believed 
to have developed in 1957 on the Thai-Cambodian border 
which spreads in all ~pidemiologically-feasible directions 
eastwards across the Ihdo China peninsula and westwards to 
Thailand within three· years (WHO, 1907). Resistance to 
amodiaquine, a 4-hydroxyaniline-substitute quinoline, 
largely follows the distribution of chloroquine resistance 
(Wernsdorfer, 1991). Under continuing chloroquine pressure 
in the core area, the parasite also showed a diminishing 
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susceptibility to amodiaquine, quinine, 
sulphadoxine-pyrimethamine and mefloquine when these drugs 
were used during the ensuing twenty years (WHO,· 1987). The 
cross resistance between proguanil, chlorproguanil and 
pyrimethamine has also been reported from different areas, 
although the patterri of cross-resistance is not uniform 
(WHO , 1 9 8 7 ) . 
Drug resistance are the results of interactions of the 
biological and epidemiological factors (Wernsdorfer, 1991). 
The degree of resistance to schizontocidal drugs has been 
classified into three categories with recommended symbols 
Rl, Rll and Rlll. Rl pattern is defined as a recrudescence 
of parasites and symptoms developed some days after 
chloroquine treatment; R11 resistance is defined as. a 
slight reduction but not elimination of parasitaemia with 
treatment and R111 is defined as the response to treatment 
· (Bruce-Chwatt,1986). 
Na lari a parasites have developed mechanisms of resistance 
against virtual~y ev~ry drug that has been used against 
them (Peters, 1982,1987; Bjorkman & Phillips-Howard ,1990). 
Therefore, steps must be taken to limit the further spread 
of resistance not only to the existing antimalarials but 
also to drugs under de~elopment. 
9 
1.1.4 Status of m~laria in Malaysia 
Malaria is still an endemic djsease of public health 
importance in Malaysia. 'l'he areas where outbreaks of 
malaria occur are mainiy confined to the central areas of 
the country which is hilly and undeveloped . The incidence 
of- malaria declined from 61,593 cases with 223 deaths in 
1971, to 44,488 cases with 53 deaths in 1980 {Singh,1985; 
Chooi, 1985). Malaria incidence from 1982 to 1987 (up to 
July) was 24,228 cases with 43 deaths, showing a decline on 
the death cases {Uma & Chee ,1988) by Jan-Sept 1993 
{recently summarized malaria cases showed in index) the 
incidence was 28,881 cases with 12 deaths. 25.8% of the 
total cases were from peninsular Malaysia, 2.7% from 
Sarawak and 71.4% from Sabah. 
Control of falciparum malaria remains one of the world's 
~----------~----------------
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greatest health chalienl]es. Generally, prevention of 
malaria can be tackled by chemotherapeutic (diagnosis and 
treatment of established infections), vector control, 
vaccination (under development) and health education. 
Drug is an important el~rnent of malaria control, especially 
in .... areas where insecticJdes is less or not effective. 
Resistance of h falciparum to 4-aminoquinolines has 
developed severe clinibal forms of the disease • Therefore 
there is a continuing n~ed for new , inexpensive drugs that 
are effective against resistant strains of -~ falciparum , 
which are safe for fiel~ use and can be administered orally 
in a single dose. 
Much attention has beert directed to the development of new 
antimalarial drugs with less side effects especially drugs 
for severe malaria. The improvement of drug formulation and 
its efficacy for example ha lofantrine, artemis in in and 
its derivatives, benflumetol and etc. ( WHO,l990) may fulfil 
the needs. 
Combination of drugs m~y give effective protection against 
malaria. For example, the combination of pyrimethamine and 
sulphadoxine and chlorproguanil with dapsone were equally 
effective for treatment of falciparum malaria which is 
superior to chloroquine Jn non-pregnant and pregnant women 
(Keuter et al, 1990). chloroquine combination with calcium 
antagonists to "reverse" resistance has also been 
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demonstrated in vivo. 'l'hese observations have stimulated 
several groups to consider using chloroquine in combination 
with calcium antagonj_sts for the treatment of 
chloroquine-resistant m~laria infections (WHO,l990). 
Another approach which is still under development to 
eradicate malaria is by vaccination ( Arnold,l990). Malaria 
vaccines should be used to solve problems in areas where 
malaria control has run into technical difficulties and in 
areas where control was not possible Three main 
approaches to vaccination are the antj -sporozoites, 
anti-merozoite or anti-asexual blood stage and anti-gamete. 
The development of an anti-sporozoite vaccine against ~ 
falciparum was based on defined polypeptides produced 
either by genetic engineering or chemical synthesis. 
Vaccines directed against asexual blood stages would 
probably curb mortality and morbidity and be particularly 
useful in areas with intensive malaria transmission 
(Arnold, 1990) . 
However, it was important to bear in mind that the clinical 
and epidemiological aspects of vaccine development are 
extremely complex. Gui~elines have been established for 
such work by WHO but many questions regarding safety, 
frequency of vaccinatidn, appropriate adjuvants, possible 
immunopathological sequelae and ultimate ability to afford 
prot<~ction against natural sporozoite challenge for 
different ages of people so far unanswered. 
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1.2 Review of analytical methods 
In this thesis I works focus on biguanide antimalarials 
and therefore this sec~tion aims to give the review of 
the analytical work that have been done. 
'l'he earliest and most frnquently used method of assay fo:,:-
this drug (Proguanil) in tissues and body fluids is by 
making.the sample alkaline and extracting it into organic 
solvent, which is then acidified and extracted back into an 
aqueous phase (Spinks and Totteyl 1945 ; Maegraith et al, 
1946 ;Schmidt et al I 1947 and Smith e~ al ,1961). The p-
chlorophenylanaline i~ being released by autoclaving which 
caused a hydroly-tic cleavage. The diazotisable amines is 
then determined by the Bratton-Marshall procedure. However 
this method allows quantification in the range of 1-50 
, · tig/ml and is relatively insensitive. Smith et .?1 ( 1961) 
Armstrong (1973) proposed another method which measured 
microbiologically the inhibition of growth of the 
folate-requiring bacterium Streptococ<;us faci_um (ATCC8043). 
Generally, the spectr6photometric and bioassay methods have 
poor reproducibilit~ in comparison with more pr0cise 
physicochemical methods, and consequently they require a 
more complex assay design. Determination of in vivQ. 
bioavailability and pharmacokinetic profile in man require 
assay which is both sensitive· and specific for the parent 
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drug or its major metabolites (Schwartz & de Silva, 
(1978). Blood concentrations of the parent drug may be 
hardly measurable due to the low dose administered, a high 
volume of distribution, 
elimination of the drtig. 
rapid biotransformation and 
Chromatographic techniques using High Performance Liquid 
Chromatography (HPLC) and Gas Chromatography (GC) are more 
advantageous because they possess the required sensitivity 
and specificity. The review of various published analytical 
methods by these chromatographic techniques for the 
determination of progtianil, chlorproguanil and their major 
metabolites has been summarised in Table 1. 
1. 3 Review of pharmacokinetic and meta_bolism 
Ph~rmacokinetics is a mathematical description of the 
process of absorption, distribution into and within tissues 
and elimination which relates the dose given, the 
concentration in the blood and the pharmacological 
response. 
From the calculation o~ pharmacokinetic parameters, one can 
predict the drug concentrations as a function of time, 
dosage and route of administration. In addition, these 
parameters can be used to evaluate the effect of factors 
such as genetics, disease, other drugs and environmental 
conditions on drug disposition. 
Table 1 : SumMary of chromatographic analytic~! methods for proguanil and chlorproguanil in biological fluid. 
Compound Method of Extraction Colufln Mobile phase 
analysis method 
Proguanil HPLC Solid phase ODS-Hypersil Acetonitrile-10% 
cycloguanil 
chlorophenrl· 
biguanide 
(CPB) 
Proguanil 
cycloguanil 
Proguanil 
cyclogu11nil 
Proguanil 
cycloguanil 
CPB 
Chlorproguanil 
. Chlorcyclo-
guanil 
HPLC 
HPLC 
HPLC 
HPLC 
extraction Sua w/v(l: 1) SLS + 
Acetonitrile-water 
(SO:SO) t 0.17SM 
phosphoric acid + 
0.0125 NaH2Po4 (pH=l. 5) 
Liquid-liquid Spherisorb 
extraction nitrlle 
Sum 
Liquid-liquid Supelco-NH2 
extraction Sum x 2Sc• 
X 461DRI 
Solid phase ODS-Hypersil 
extraction 3UII 
Liquid- I I quid Spherisorb 
extraction phenyl SUI 
Acetonitrile-
aethanol-wster 
(9:2:89 v/v) + 
0.0511 AuoniUII 
formate 
(pH=4.0) 
Methanol-0.5% 
NH 3 (2S~) + Acetonitrile(1:1) 
Acetonitrile-lOnM 
aqueous phosphate 
buffer (pH=2) + 
200aM SLS (SO:SO) 
Acetonitrile-water 
containing SmM 
1-pentanesulphonic 
acid (35:65) 
(pH=3.8) 
Limit of Detection 
60ng/al 
10ng/al 
Proguanil 
O.llug/111 
cycloguanil 
0.05ug/al 
Cycloguanil 
O.Sng/111 
CPB-O.Sng/al 
proguanil 
1. Ong/al 
Chlorproguanil 
Sng/al 
chlorcycloguanil 
10ng/~al 
Author 
Moody, 
Selkirk & 
Taylor 
(1980) 
Kelly & 
Fletcher 
(1986) 
Bygbjerg & 
Flachs 
(1986) 
Taylor 
et tl 
( 1987) 
Edstein & 
Veenendal 
(1987) 
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Classical pharmacokineti.cs has developed sophist i.cated 
techniques for the anal.ysis of drug conditions versus time. 
This has proven valuable in a variety of applications 
concerning drug action and usage. The main emphasis has 
been in the use of descriptive models (compartmental 
models). Although a f~w of the derived parameters may have 
direct physiological r~ality, for example blood clearance, 
the majority of these have no immediate association with 
the in : v :lY.Q pro c e s s . ( G i b a 1 d i & Per r i e r , 1 9 8 2 ~ Wagner 
1976). Therefore ther~ has been a tendency to overlool< the 
fact that data from the experiment is the end of the 
interaction of 
processes. These 
a number of controlling biological 
limitations however, has led to the 
development of more bhysiologically oriented models of 
drug disposition which permit identification of the role 
and importance of certain in vivo processes. 
Shand, 1975, Rowland and Tozer, 1989). 
(Wilkinson & 
Pharmacokinetic parameters are derived from time related 
changes in the concentration of drug and metabolite in 
plasma, whole blood or urine. Almost all of pharmacokinetic 
parameters in this thesis will be based on the analysis of 
·plasma and metabolite cbncentration versus time data, using 
model independent formulae according to the method 
outJjned below. This approach clearly discriminates between 
alterations in the rate· of change in drug concentrations 
with time and also preSents changes in drug concentration, 
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which usually occur e~ponentially, as linear processes. 
The absorption of drud from the site of administration i.e. 
absorption phase may be followed by one or more 
distributive phases wher.~ clrug concentrations decline due 
to distribution throughout the body. Finally there is the 
elimination phase, where drug concentrations decline due to 
irreversible loss of drug from the body. 
Generally, the Tates of the above processes 
first-order kinetics and are proportional to 
concentration of drug in the body. However, there 
obey 
the 
are 
exceptions and a number of compounds exhibit non-linear or 
zero order kineties and can be described by the 
Michaelis-Menten equation (Gibaldi & Perrier, 1982). The 
methods used in this thesis to determine pharmacokinetic 
parameters apply only to drugs which obey linear, first 
order kinetics and may be divided into 2 categories: 
primary, pharmacokinetic parameters i.e, clearance and 
volume of distribution and secondary or clerived"parameters 
including elimination half life and area under the drug 
concentration versus ti~e curve. Alterations in the values 
of primary parameters (;an be reflected by changes in the 
value of the secondary parameters. 
1. 3.1 Pha_r_QH!,CO~inetic Principles 
Pharmacokinetics describe the quantitative analysis of the 
• 
1'/ 
processes of drug absorption, distribution 
and excretion. 
1.3.1.1 Drug ab~orption. 
elimination 
Drug which are administered extravascularly and required to 
act systematically must first be absorbed. This involves 
the transfer of drug in solution across the separating 
biological membranes from the site of administration to the 
site of measurement. The rate and extent of the absorption 
process can have marked effects on the time of onset, 
intensity and duration of a pharmacological response 
produced by a drug. The mechanism of drug absorption is 
generally by passive diffusion of a drug down a 
concentration gradient from the gut to the blood stream 
with no expenditure of energy or by active transport which 
requires expenditure of energy 1 filtration through pores 
and by pinocytosis. Factors which influence the absorption 
of a drug include dissolution churacteristics I molecular 
weight, pKa, lipophilicity, environmental pH, blood flow 
and gastric mobility. 
The term bioavailabil~ty or systemic availability is used 
to describe the fraction of a drug which is transported 
from its site of administration to the site of measurement 
usuully by systemic circulation. 
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1.3.1.2 Drug distribtJ1~..1gn 
Fol.J.m.;ing the entry into systemic circulation, a drug has 
to distribute throughout the body. Distribution is a 
reversible transfer process and it depends on the 
physicochemical characteristics of the drug, blood flow to 
vtrr i.ous tissues and the binding of the drug to various 
tissue components and plasma proteins. Basic clJ·ugs may 
also bind to acute phase proteins such as OC-1-aci.d 
glycoprotein. Once distribution is complete drug 
concentrations throughout the body are at equilibrium. 
Alterations in plasma drug concentration will then reflect 
" 
similar changes in tissues concentrations throughout the 
body. 
1.3.1.3 R_ruq eliminatign. 
Drug elimination is the irreversible loss of drug from the 
body by the process o t m<~tabolism and excretion. The rna in 
site of drug metabolism is primarily the liver and other 
tissues inc .luding kidney, skin, lung, bl oocl, p] acenta and 
intestinal mucosa while the main routes of excretion are 
via elimination in b'ilE~ or urine although there are 
instances when drugs have been excreted in swPat, saliva, 
~xpired air and natural milk (Gilbaldi, 1984). 
The rate of drug met abo 1 is111 usually varies i.ndi v Jdually 
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nnd usually is determjnect genetically but can be changed by 
environmental factors such as age, the environment, 
smoking, diet and alcohol. Biotransformation of many drugs 
prodllce metabolites that are less pharmacologically active 
(detoxification). However, certain metabolites have greater 
biological activity t~1an the parent compound. Here, the 
parent compound is a · prodrug' and the biotransformation 
product is a metabolite with a pharmacological action, for 
example, proguanil and chlorproguani 1 (Carrington, et al, 
1951). · The toxic effects of some drugs are caused by 
metabolites, for example paracetamol (Potter, et __iil, 
1973) . 
The biotransformatjon of foreiqn compounds is catalysed by 
a wider variety of enzyme systems. The most important of 
which are the cytochrome P-450 mixed function oxygenase 
(Park, 1982). There are two types of biotransformation, 
phase 1 reactions are oxidation, reduction or hydrolytic 
procr:-")sses while phase I I react ions in valve conjugation of 
drug to an enclog(~nous molecule such as glucuronic acid, 
sulphate, amino acids or qlutathione. 
A large number of drug biotrartsformation have been shown to 
be catalysed by l;)llzymes located on the smooth endoplasmic 
reticulum of hepatocytes. 'I'hese enzymes have been named 
microsomal as they can be isolated from microsomes, which 
are small vesicles fotrned aftc~r mec!Janicill (ljsruption of 
the endoplasmic reticulum. C y c t o c h t' o m e P - 4 5 0 i s a 
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haemoprotein which is tho terminal oxidase involved in 
hy(lroxy.lat ion of numerou!.i druqs and endogenous compounds, 
for example steroids. This haemoprotei.n exists ln a number 
. 
of for111s of isozyrnes and the relative proportions of each 
are determined by fact6rs such as species, genetics and 
environmental jnfluences. (I3rof;en, 1990; Gonzalez, 1988, 
Guengerich & West, 1989 ; Boobis & Davis, 1984; Lu & West, 
19BO). Drug rnetabolising enzymes also have been isolated 
from other sources such as mitochondria, lysosomes, nuclei 
and cytosol. 
1.3.1.4 
Ex c J.' e t .i o n i s t h e p t o q ~ s !> b y w h i c h d r u g s a n d t h e i r 
metabolites are remove~ from the body. The major pathways 
are the renal and bi.liary excretion, und also occur in 
ot~er biological fluids. 
In rena 1 excretion, di·ugs and metabolites wi 11 undergo n 
glomerular filtration and will be forced ncross the renal 
tubular ce 11 by an act l ve transport mechanism fl9<d.JH> t a 
concentration gradient. Certain compounds are subject to 
t u b u 1 a r· r e a b s o r p t i o n d u e L o t h e i 1: p h y s i c o c h e m i c a 1 
properties. 
Drugs may be excreted by hepatic cells into the bile. They 
are occasionally excreted unchangecl but more usually as 
conjugates (e.q. glucuronic acid, sulphate ancl qlyci.nn 
?1 
conjugates) . In genera J, polar metabolites secreted into 
the bile have relative mol~~cular masses > 400. Drug 
conjugate complex is a good candidate for bilary excretion 
d u e t o t h e i n c r e a s e d m o l e c u J. a r we i. g h t . D r· u g a n d i t s 
metabolites which are secreted into the bile and hence into 
the small intestine can undergo reabsorption into· the 
systemic circulation and this process is termed 
enterohepa tic recirculation ( EHC) • Thus, the EJIC is a 
mechanism which prolongs the action of a drug. 
Elimination half-life if.:: defined as the time taken for 
plasma drug concentration and therefore the amount of drug 
in the body to fall by one-half after the attainment of 
distribution equilibrium. This value is a constant for a 
drug obeying first-order elimination kinetics and is 
independent of the amount of drug in the body. 
There~ fore, the amount of drug eliminated decreases in 
successive half-live. In theory, the drug can never be 
comp] etely removed from the body, however, in practical 
tet·ms, elimination is accepted as being complete aftE!r 5 
half-lifes have elasped whereby 97% of this has been 
!'(~moved. 
'l'he elimination half-life can be determined from the 
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sem:i.-log plot of drug concentration versus time and can be 
calculated as shown below: 
tl/2 = time for the concentration to decrease 
by hill. f. 
tl/2 = ln2/k = 0.693/k 
1.3.2.2 Clearahce (C_!J_ 
DrttcJ c 1 earances describe thr~ relationship b<~ tween the rate 
of drug elimination cmd drug concentration and is the most 
us<~ful parameter tor tlH~ evaluat.ion of an elimination 
mechanism. Clearance i~> the volume of a biological fluid 
from which drugs is removed per unit time. 
The v~lue of clear~nce is dependent upon the site of 
m <~a s u rem en t but in de p e n dent o C c once n t r a t ion for drugs 
whiclt obey first-order elimination kinetics (i.e. clearance· 
is constant}. Total systemic clearance (CL) is the sum of 
all metabolic and excretory clearance processes which is 
the sum of all organ clearances. If the assumption is made 
that drug is completely metabolized by one organ e.g.: the 
liver, clearance is equal to the blood flow through the 
organ , therefore the equation can be written as : 
CL 
k 
= 
= 
kVcl 
eljmination rate constant 
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There is an inter- rela t iunsh ip between the clearance of a 
drugs, apparent volume of d.istr.ibution and elimination 
half-life as follows: 
CL = kVd 
Since k = 0.693/tl/2 
CL = 0.693Vd/t 1 ; 2 
tl/2 = 0.693 Vd/CL 
Hence, CL = kVd 
1.3.2.:~ 
This parameter relates the total amount of drug in the body 
to the measurement of drug concentration when distribution 
equilibrium has been achieved i.e. 
Vd 
Vd 
Ab 
Cp 
= 
= 
= 
= 
Ab/Cp 
Volume of distribution 
the amount of drug in the body 
the measured drug concentration 
'l'he value of this parameter rarely corresponds to a real 
physiological volume and is largely dependent upon the 
plasma and tissue bindinq of 1·.1Je drug, in addition to the 
physicochemical prop~rties of the drug which determine the 
extent to which it will partition irJto biologjcal membrane. 
'l'he volume ot distribution can be calculated from plasma 
concentration versus time data as follows: 
Vel = dose/AUC k 
AUC = Area under curve 
k = elimination rate constant 
1.4 Jeview of drug available 
AntJmn.lnrial drugs which are currently in use or have 
reached advance stages of alinical trials can be classified 
as follows: 
(a) Cinchona alkaloidu e.g. quinine nnd quinidine. 
(b) 4-aminoquinolines e.g. cl1loroquine and amodiaquine. 
(c) 8-amirioquinolines e.g. primaquine. 
(d) Quinolinemethanols e.g. mefloquine. 
(e) The antifolates co~prising; 
Dihydrofolate reducta~e inhibitors e.g. proguanil1 
chlorproguanil 1 cyclogtianil and pyr':i:methamine. 
sulphonamides - e.g. sulphadoxine. 
sulphones - e.g. dapsones. 
(f) Antibiotics ·- e.g. ;tetracyc 1 ine ~ ,1·~< ; . 
( q) 
(h) 
• Thl.'1 phenanthrenemethanols - e.~ g >.llaJofantr ine. 
The sesquiterpen~ ~ lactones 
ar Lns una te I artoettwr and a r· Lr:me Lhe r·. 
artemisininl 
